Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Celcuity ( (CELC) ) has issued an announcement.
On October 18, 2025, Celcuity Inc. announced significant results from their Phase 3 VIKTORIA-1 clinical trial at the ESMO Congress, highlighting the efficacy of gedatolisib regimens in treating HR-positive, HER2-negative, PIK3CA wild-type advanced breast cancer. The trial demonstrated that the gedatolisib triplet and doublet regimens significantly improved median progression-free survival compared to fulvestrant, marking a potential new standard of care for patients whose disease progressed after CDK4/6 inhibitor treatment. The company is advancing a New Drug Application with the FDA based on these findings, aiming for completion by the end of 2025.
The most recent analyst rating on (CELC) stock is a Buy with a $68.00 price target. To see the full list of analyst forecasts on Celcuity stock, see the CELC Stock Forecast page.
Spark’s Take on CELC Stock
According to Spark, TipRanks’ AI Analyst, CELC is a Neutral.
Celcuity’s stock score of 43.73 reflects the challenges faced by early-stage biotech firms. The company’s financial performance is weak due to lack of revenue and high expenses. Technical analysis shows a neutral to slightly negative outlook, while valuation metrics are poor due to negative earnings. Despite these challenges, the earnings call provided a positive outlook with potential future revenue and strong financial positioning. The overall score indicates significant risks but potential for future growth if clinical and financial milestones are achieved.
To see Spark’s full report on CELC stock, click here.
More about Celcuity
Celcuity Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for oncology, specifically for hormone receptor-positive, HER2-negative advanced breast cancer.
Average Trading Volume: 1,585,596
Technical Sentiment Signal: Buy
Current Market Cap: $2.2B
See more data about CELC stock on TipRanks’ Stock Analysis page.